About the Neuroscience Forum
The IOM in 2006 established the Forum on Neuroscience and Nervous System Disorders. The forum is designed to provide its members with a venue for exchange of information, sharing individual views, and allowing a structured opportunity for dialogue and discussion while scrutinizing, critiquing, and possibly contentious scientific and policy issues. Representatives from government, industry, academia, patient advocacy organizations, and other interested parties serve as Forum members. It convenes three times a year to create an expert venue of mutual interest and concern. At its meetings, the forum identifies and discusses emerging scientific and policy issues related to basic neuroscience and nervous system disorders, as well as effective clinical interventions and public policy. The Forum also sponsors workshops temporarily as an additional venue for informing the membership of the Forum, other relevant stakeholders, and the public. Information about past or upcoming meetings is available at the Forum’s website, www.iom.edu/neuroforum.

About the Institute of Medicine
The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. The mission of the Institute of Medicine endorses the health of people everywhere.

IOM Staff
Bruce Altevogt, Ph.D. Project Director
Sarah Hansen Associate Program Officer
Lisa Taylor Service Project Assistant

IOM Board on Health Sciences Policy
Andrew M. Page, Ph.D. Director

THE NATIONAL ACADEMIES
Aid to the Nation on Science, Engineering, and Medicine

For additional information on the Forum on Neuroscience and Nervous System Disorders visit the Forum’s website at www.iom.edu/neuroforum, or call Bruce Altevogt at (202) 334-3984.

FORUM MEMBERSHIP
(AAS OF DECEMBER 2009)

Alan Lebowe (Chair)
American Association for the Advancement of Science

Hassaini Maraj
Johnson & Johnson Pharmaceutical

FORUM SPONSORSHIP
Financial support for the Forum is derived from federal agencies, patient advocacy organizations, industry, and a non-profit membership society.

Alzheimer’s Association
AntiAlzheimer Pharmacology
Cerebral Amyliase
El Lilly and Company
GI Healthcare
GlaxoSmithKline
Hospira Inc.
Johnson & Johnson Pharmaceuticals
Wyeth Research

The Michael J. Fox Foundation for Parkinson’s Research
National Institutes of Health: National Institute on Aging
National Institutes of Health: National Institute on Drug Abuse
National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism
National Institutes of Health: National Institute of Neurological Disorders and Stroke
National Institutes of Health: National Institute on Aging
National Institutes of Health: National Institute on Drug Abuse
National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism

Wyeth Research

For additional information on the Forum on Neuroscience and Nervous System Disorders visit the Forum’s website at www.iom.edu/neuroforum, or call Bruce Altevogt at (202) 334-3984.

Steve Hyman welcomes participants to the workshop on Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa, August 2009
Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa

In August, the Forum, in collaboration with the Forum on Health and Nutrition of the Uganda National Academy of Sciences, convened a workshop on Advances in research on the neurosciences, in health and sickness, including the potential application to healthcare delivery. A large emphasis will be on discovering the scientific principles that should be considered when designing pro-collaboration programs that require more than just the approval of various stakeholders. The Forum’s website (www.iom.edu/neuroforum) will be updated to reflect these new activities.

Sex Differences and Implications for Translational Neuroscience Research

The Forum is hosting a workshop to explore the key principles and strategies used by basic translational neuroscience researchers, biopharmaceutical industry, and pharmaceutical industry in the design of research for the Alzheimer’s disease research network.

Glutamate-related Biomarkers for Disorders of the Nervous System

The goal of this workshop is to gain an enhanced understanding of the role of biomarkers, as indicators of when and how sex differences should and should not be considered; and, how to bridge the interface between what pharmaceutical and diagnostic developers are looking for and how academic researchers can best contribute to the partnership in a meaningful way in order to improve the neuroscience-translational research pipeline.

Social Issues in Neuroscience

A comprehensive and independent evaluation of neuroscientists in a dialogue about the critical time neuroscience is entering with regard to ethical and social implications of research findings as the field continues to find the scientific underpinnings for pre-clinical and clinical studies; when and how sex differences should and should not be considered; and, how to bridge the interface between what pharmaceutical and diagnostic developers are looking for and how academic researchers can best contribute to the partnership in a meaningful way in order to improve the neuroscience-translational research pipeline.

FORUM ACTIVITIES FOR 2010

Sex Differences and Implications for Translational Neuroscience Research

The Forum is hosting a workshop to explore the key principles and strategies used by basic translational neuroscience researchers, biopharmaceutical industry, and pharmaceutical industry in the design of research for the Alzheimer’s disease research network.

Meeting on translating research and development for schizophrenia.

CNS Clinical Trials: Suicidality and Data Collection

The Forum, in conjunction with the National Research Council’s Committee on Science, Technology, and Law and the Institute for Laboratory Animal Research, will plan and assist in a workshop that will provide an overview of the issues facing researchers and industry in studying sex differences in the neurosciences for the therapy development pipeline. Discussions and presentations will also focus on how to bridge the interface between what pharmaceutical and diagnostic developers are looking for and how academic researchers can best contribute to the partnership in a meaningful way in order to improve the neuroscience-translational research pipeline.

Social Issues in Neuroscience

The Forum, in conjunction with the National Research Council’s Committee on Science, Technology, and Law and the Institute for Laboratory Animal Research, will plan and assist in a workshop that will provide an overview of the issues facing researchers and industry in studying sex differences in the neurosciences for the therapy development pipeline. Discussions and presentations will also focus on how to bridge the interface between what pharmaceutical and diagnostic developers are looking for and how academic researchers can best contribute to the partnership in a meaningful way in order to improve the neuroscience-translational research pipeline.

Social Issues in Neuroscience

The Forum, in conjunction with the National Research Council’s Committee on Science, Technology, and Law and the Institute for Laboratory Animal Research, will plan and assist in a workshop that will provide an overview of the issues facing researchers and industry in studying sex differences in the neurosciences for the therapy development pipeline. Discussions and presentations will also focus on how to bridge the interface between what pharmaceutical and diagnostic developers are looking for and how academic researchers can best contribute to the partnership in a meaningful way in order to improve the neuroscience-translational research pipeline.

Grand Challenges in Neuroscience

The Forum, in conjunction with the National Research Council’s Committee on Science, Technology, and Law and the Institute for Laboratory Animal Research, will plan and assist in a workshop that will provide an overview of the issues facing researchers and industry in studying sex differences in the neurosciences for the therapy development pipeline. Discussions and presentations will also focus on how to bridge the interface between what pharmaceutical and diagnostic developers are looking for and how academic researchers can best contribute to the partnership in a meaningful way in order to improve the neuroscience-translational research pipeline.
Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa

As August approaches, in collaboration with the Forum on Health and Nutrition of the Uganda National Academy of Sciences, convened within the 10th Forum on Neuroscience in Uganda, quality of care in the movement for the change of care systems for mental, neurological, and substance use disorders in Sub-Saharan Africa. In light of the economic interests of the most vulnerable African countries, the workshop set out to explore areas where policies might improve care, opportunities to better understand the context of change and sustainability within a country’s health care system, and measures that are currently available in order to build the capacity of local and regional partners. Workshop participants were encouraged to map and use resources with significant implications for disease control, in order to come up with policy frameworks and understanding of the challenges that will be faced by the region.

2009 SfN Annual Meeting: Social Issues Roundtable

The Forum organized the Social Issues Roundtable at the 2009 meeting of the Society for Neuroscience. The purpose of the roundtable was to initiate a dialogue among those attending the Roundtable about the social and ethical implications of research findings as the field continues to find the scientific underpinnings of the rest of society. Speakers and researchers addressed current social issues in research and some are deciding future restrictions for certain animals. The meeting sparked interest in the debate among lawyers in the United States and elsewhere to develop strategies to improve the understanding of the role of biomarkers, as well as academic and other researchers. The working group presented a post-mortem on the social issues in the neurosciences.

Facilitating Translational Research for Clinical Neuroscience Applications

Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of Health join members of the Forum in a meeting on translational research for clinical neuroscience applications. The current meeting will focus on defining the research needed to fill the translational research pipeline. Discussions and presentations will also focus on how to bridge the interface between basic and clinical research.

Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa

In light of the economic interests of most vulnerable African countries, the workshop set out to explore areas where policies might improve care, opportunities that could be used to better ensure continuity of care and social implications of research findings as the field continues to find the scientific underpinnings of the rest of society. Workshop topics often originate from working groups and are organized by an international member of the Forum's scientific advisory committee.

Translational Neuroscience

The translational neuroscience working group was established to focus on identifying areas of synergy where public and private sector stakeholders can partner to improve the efficiency and effectiveness of drug and diagnostic development for neurological and mental disorders. The group is currently developing a working agenda aimed at improving the understanding between what pharmaceutical and diagnostic developers are looking for and academic researchers can best contribute to the partnership.

Social Issues in Neuroscience

A working group of international neuroscientists was developed in a collaborative effort to identify the translational neurosciences. The social issues working group is exploring the opportunities, evaluating social and ethical implications of research findings. The findings can be used to focus on social issues in neuroscience.

Looking Ahead: Forum Activities for 2010

Sex Differences and Implications for Translational Neuroscience Research

The Forum is hosting a workshop to explore the key principles and strategies used by basic translational neuroscience and industry, with an emphasis on differences in the methodologies for the design and conduct of experiments. The workshop will focus on improving the public health importance of studying sex differences in neuroscience. The forum is held in coordination with the Forum on Neuroscience in Uganda, quality of care in the movement for the change of care systems for mental, neurological, and substance use disorders in Sub-Saharan Africa.

Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa

The Forum organized the Social Issues Roundtable at the 2009 meeting of the Society for Neuroscience. The purpose of the roundtable was to initiate a dialogue among those attending the Roundtable about the social and ethical implications of research findings as the field continues to find the scientific underpinnings of the rest of society. Speakers and researchers addressed current social issues in research and some are deciding future restrictions for certain animals. The meeting sparked interest in the debate among lawyers in the United States and elsewhere to develop strategies to improve the understanding of the role of biomarkers, as well as academic and other researchers. The working group presented a post-mortem on the social issues in the neurosciences.

Facilitating Translational Research for Clinical Neuroscience Applications

Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of Health join members of the Forum in a meeting on translational research for clinical neuroscience applications. The current meeting will focus on defining the research needed to fill the translational research pipeline. Discussions and presentations will also focus on how to bridge the interface between basic and clinical research.

Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa

In light of the economic interests of most vulnerable African countries, the workshop set out to explore areas where policies might improve care, opportunities that could be used to better ensure continuity of care and social implications of research findings as the field continues to find the scientific underpinnings of the rest of society. Workshop topics often originate from working groups and are organized by an international member of the Forum's scientific advisory committee. The forum is held in coordination with the Forum on Neuroscience in Uganda, quality of care in the movement for the change of care systems for mental, neurological, and substance use disorders in Sub-Saharan Africa.

Translational Neuroscience

The translational neuroscience working group was established to focus on identifying areas of synergy where public and private sector stakeholders can partner to improve the efficiency and effectiveness of drug and diagnostic development for neurological and mental disorders. The group is currently developing a working agenda aimed at improving the understanding between what pharmaceutical and diagnostic developers are looking for and academic researchers can best contribute to the partnership.

Social Issues in Neuroscience

A working group of international neuroscientists was developed in a collaborative effort to identify the translational neurosciences. The social issues working group is exploring the opportunities, evaluating social and ethical implications of research findings. The findings can be used to focus on social issues in neuroscience.
Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa

In August, the Forum, in collaboration with the Forum on Health and Nutrition of the Uganda National Academy of Sciences, convened a meeting of experts in Uganda to examine the nature of the challenges for the research on substance use and psychiatric disorders in Sub-Saharan Africa. The meeting was held at the Forum's headquarters in Kampala, Uganda and was attended by researchers from across the region. The meeting was attended by researchers from across the region and emphasized the need for more research, intervention, and communication by all stakeholders, national and international. The summary of the meeting will be released in Spring 2010 and will be found on the Forum's website (www.nsf.org).

2009 SfN Annual Meeting: Social Issues Roundtable

The Forum organized the first Social Issues Roundtable at the 2009 meeting of the Society for Neuroscience. The purpose of the discussion is to examine the ethical considerations that are relevant to social and implications of research findings as the field continues to find the scientific underpinnings of what is considered the self, soul, free will, or what it means to be human. Speakers from the Academy of Sciences, convened an international workshop in Kampala, Uganda on quality of care issues for mental, neurological, and substance use disorders in Sub-Saharan Africa. In light of the economic limitations of most sub-Saharan African countries, the workshop set out to explore areas where public policies might impact on options to improve the quality of care within a sustainable health care system, and measures that are presently available or could be made available to the region’s stakeholders. The workshop emphasized the need for more action, intervention, and communication by all stakeholders, national and international. The summary of the meeting will be released in Spring 2010 and will be found on the Forum's website (www.nsf.org).
Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa

In August, the Forum, in collaboration with the Forum on Health and Nutrition of the Uganda National Academy of Sciences, convened a workshop in Uganda on quality of care in mental health treatment for depression and anxiety among adults and children, and on care for children left behind who have lost a caregiver. The workshop emphasized the need for action, investment, and commitment by all stakeholders, national and international. The summary of the workshop will be released in Spring 2010 and will be found on the Forum’s website (www.iom.edu/neuroforum).

Sex Differences and Implications for Translational Neuroscience Research

For the Forum is hosting a workshop to explore the key principles and strategies used by basic translational neuroscience researchers and industry. Sex differences exist in the neuroscience for drug development path. Speakers will outline the public health importance of studying sex differences in the nervous system, in health and sickness, including the potential application to healthcare delivery. A large emphasis will be on the increasingly scientific principles that will be considered when design- ing pre-clinical experiments that will examine sex differences, including strategies to bridge between preclinical and clinical research. The discussion will focus on how to foster and encourage new research directions and the key principles and strategies used by academic clinicians to effectively utilize basic research for pre-clinical and clinical applications and study.

Facilitating Translational Research for Clinical Neuroscience Applications

Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of Health will join members of the Forum in a meeting on translational research for clinical neuroscience applications. The meeting will stimulate discussions aimed at improving the understanding between what pharmaceutical and diagnostic developers are looking for and how academic research can best contribute to improving research efficiency and development of promising tools for pre-clinical and clinical research applications. Discussions and presentations will all be in small groups that will bring together pharmaceutical and diagnostic representatives with basic neuroscience researchers. The meeting will stimulate discussions aimed at improving the understanding between what pharmaceutical and diagnostic developers are looking for and how academic research can best contribute to improving research efficiency and development of promising tools for pre-clinical and clinical research applications. The meeting will be held in early 2010 through the Forum’s website (www.iom.edu/neuroforum).

FORUM ACTIVITIES FOR 2010

Sex Differences and Implications for Translational Neuroscience Research

The Forum is hosting a workshop to explore the key principles and strategies used by basic translational neuroscience researchers and industry. Sex differences exist in the neuroscience for drug development path. Speakers will outline the public health importance of studying sex differences in the nervous system, in health and sickness, including the potential application to healthcare delivery. A large emphasis will be on the increasingly scientific principles that will be considered when designing pre-clinical experiments that will examine sex differences, including strategies to bridge between preclinical and clinical research. The discussion will focus on how to foster and encourage new research directions and the key principles and strategies used by academic clinicians to effectively utilize basic research for pre-clinical and clinical applications and study.

Facilitating Translational Research for Clinical Neuroscience Applications

Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of Health will join members of the Forum in a meeting on translational research for clinical neuroscience applications. The meeting will stimulate discussions aimed at improving the understanding between what pharmaceutical and diagnostic developers are looking for and how academic research can best contribute to improving research efficiency and development of promising tools for pre-clinical and clinical research applications. Discussions and presentations will all be in small groups that will bring together pharmaceutical and diagnostic representatives with basic neuroscience researchers. The meeting will stimulate discussions aimed at improving the understanding between what pharmaceutical and diagnostic developers are looking for and how academic research can best contribute to improving research efficiency and development of promising tools for pre-clinical and clinical research applications. The meeting will be held in early 2010 through the Forum’s website (www.iom.edu/neuroforum).

FORUM ACTIVITIES FOR 2010

Sex Differences and Implications for Translational Neuroscience Research

The Forum is hosting a workshop to explore the key principles and strategies used by basic translational neuroscience researchers and industry. Sex differences exist in the neuroscience for drug development path. Speakers will outline the public health importance of studying sex differences in the nervous system, in health and sickness, including the potential application to healthcare delivery. A large emphasis will be on the increasingly scientific principles that will be considered when designing pre-clinical experiments that will examine sex differences, including strategies to bridge between preclinical and clinical research. The discussion will focus on how to foster and encourage new research directions and the key principles and strategies used by academic clinicians to effectively utilize basic research for pre-clinical and clinical applications and study.

Facilitating Translational Research for Clinical Neuroscience Applications

Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of Health will join members of the Forum in a meeting on translational research for clinical neuroscience applications. The meeting will stimulate discussions aimed at improving the understanding between what pharmaceutical and diagnostic developers are looking for and how academic research can best contribute to improving research efficiency and development of promising tools for pre-clinical and clinical research applications. Discussions and presentations will all be in small groups that will bring together pharmaceutical and diagnostic representatives with basic neuroscience researchers. The meeting will stimulate discussions aimed at improving the understanding between what pharmaceutical and diagnostic developers are looking for and how academic research can best contribute to improving research efficiency and development of promising tools for pre-clinical and clinical research applications. The meeting will be held in early 2010 through the Forum’s website (www.iom.edu/neuroforum).

FORUM ACTIVITIES FOR 2010

Sex Differences and Implications for Translational Neuroscience Research

The Forum is hosting a workshop to explore the key principles and strategies used by basic translational neuroscience researchers and industry. Sex differences exist in the neuroscience for drug development path. Speakers will outline the public health importance of studying sex differences in the nervous system, in health and sickness, including the potential application to healthcare delivery. A large emphasis will be on the increasingly scientific principles that will be considered when designing pre-clinical experiments that will examine sex differences, including strategies to bridge between preclinical and clinical research. The discussion will focus on how to foster and encourage new research directions and the key principles and strategies used by academic clinicians to effectively utilize basic research for pre-clinical and clinical applications and study.
About the Neuroscience Forum

The IMS in 2006 established the Forum on Neuroscience and Nervous System Disorders. The forum is designed to provide its members with a venue for exchanging information, sharing individual views, and allowing a structured opportunity for dialogue and discussion while scrutinizing critical and possibly contentious scientific and policy issues. Representatives from government, industry, academia, patient advocacy organizations, and other interested parties serve as Forum members. It convenes three times a year to create a subset group of mutual interest and concern. At its meetings, the forum identifies and discusses emerging scientific and policy issues related to basic neuroscience and nervous system disorders, as well as effective clinical interventions and public policies. The financially-sponsored workshops temporally as an additional mechanism for informing the membership of the Forum, other relevant stakeholders, and the public. Information about past or upcoming meetings is available at the Forum’s website, www.iom.edu/neuroforum.

About the Institute of Medicine

The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. The mission of the Institute of Medicine endorses the health of people everywhere.

IOM Staff

Bruce Altevogt, Ph.D. Project Director
South Hansen Associate Program Officer
Lora Taylor Senior Project Assistant

IOM Board on Health Sciences Policy

Andrew M. Pope, Ph.D. Director

THE NATIONAL ACADEMIES

Members of the National Academy of Sciences, National Academy of Engineering, and Institute of Medicine

For additional information on the Forum on Neuroscience and Nervous System Disorders visit the Forum’s website at www.iom.edu/neuroforum, or call Bruce Altevogt at (202) 334-3984.

FORUM MEMBERSHIP

(AAS OF DECEMBER 2009)

Alan Leshner (Chair) American Association for the Advancement of Science
Huda Alli University of Michigan, Ann Arbor
Marc Barlow GE Healthcare
Mark Bearer Massachusetts Institute of Technology
Daniel Burch Cerebral Bohrman
Devesh Chai Jerey University
Timothy Curtin foundation of the National Multiple Sclerosis Society
David Cohen Columbia University, Society for Neuroscience representative
Richard Frank GE Healthcare
John Griffith Johns Hopkins University
Richard Hodes National Institute on Aging
Katleen Hudson The Michael J. Fox Foundation for Parkinson’s Research
Steven Hyman Harvard University
Thomas Insel National Institute of Mental Health
Stevan Lazic National Institute of Neurological Disorders and Stroke
Hassene Marji Johnson & Johnson Pharmaceutical
Lucy Marder Wyeth Research
Menelas Pangalos Merck Research Laboratories
Paul Seagard National Eye Institute
Rae Silver Columbia University
William Thies Alzheimer’s Association
Naas Yaver* National Institute on Drug Abuse
Kenneth Warner National Institute of Alcohol Abuse and Alcoholism
Frank Yocca Alcoholics Anonymous
Sarah Hanson Associate Program Officer

FORUM Sponsorship

Financial support for the Forum is derived from federal agencies, patient advocacy organizations, industry, and a nonprofit membership society.

Alzheimer’s Association
Antioxidants Pharmaceuticals
Cerebral Bohrman
BI Lilly and Company
GE Healthcare
GlaxoSmithKline
Johnson & Johnson Pharmaceuticals
Kotex
Lundbeck Research USA, Inc.
Merck Research Laboratories
The Michael J. Fox Foundation for Parkinson’s Research
National Eye Institute
National Institute on Aging

Neuroscience Forum Funding: 2009

Nonprofit 34%
Industries 32%
Federal 35%

19%
38%
43%

FORUM SPONSORSHIP

2009 ANNUAL REPORT

NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS

FORUM ON NEUROSCIENCE

AND NERVOUS SYSTEM DISORDERS

2009 ANNUAL REPORT
About the Neuroscience Forum
The IOM in 2006 established the Forum on Neuroscience and Nervous System Disorders. The forum is designed to provide its members with a venue for exchanging information, sharing individual views, and allowing a structured opportunity for dialogue and discussion while scrutinizing critical and possibly contentious scientific and policy issues. Representatives from government, industry, academia, patient advocacy organizations, and other interested parties serve as forum members. It convenes three times a year to create an expert arena of mutual interest and concern. In its meetings, the forum identifies and discusses emerging scientific and policy issues related to basic neuroscience and nervous system disorders, as well as effective clinical interventions and public policy. The forum also sponsors workshops, symposia, and possibly contentious scientific and policy issues. Representatives from government, industry, academia, patient advocacy organizations, and other interested parties serve as forum members. It convenes three times a year to create an expert arena of mutual interest and concern. In its meetings, the forum identifies and discusses emerging scientific and policy issues related to basic neuroscience and nervous system disorders, as well as effective clinical interventions and public policy. The forum also sponsors workshops, symposia, and possibly contentious scientific and policy issues.

For additional information on the forum or to become a member, please contact Bruce Altevogt at (202) 334-3984. The forum meets three times a year:

- Spring meeting: March 2010
- Summer meeting: July 2010
- Fall meeting: October 2010

The Neuroscience Forum was established as a venue for dialogue and discussion while scrutinizing critical and possibly contentious scientific and policy issues. Representatives from government, industry, academia, patient advocacy organizations, and other interested parties serve as forum members. It convenes three times a year to create an expert arena of mutual interest and concern. In its meetings, the forum identifies and discusses emerging scientific and policy issues related to basic neuroscience and nervous system disorders, as well as effective clinical interventions and public policy. The forum also sponsors workshops, symposia, and possibly contentious scientific and policy issues.

About the Institute of Medicine
The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. The Institute of Medicine endorses the health of people everywhere.

IOM Staff
Bruce Altevogt, Ph.D. Project Director
Sarah Henson Associate Program Officer
Lisa Taylor Senior Project Assistant

IOM Board on Health Sciences Policy
Andrew M. Pogue, Ph.D. Director

THE NATIONAL ACADEMIES
Alliances to the National Academy of Sciences, Engineering, and Medicine

FORUM MEMBERSHIP
(As of December 2009)

Alan Lubber (Chair)
Andrew M. Pope, Ph.D.
Bruce Altevogt, Ph.D.
Lora Taylor
Sarah Hanson

FORUM SPONSORSHIP
Financial support for the Forum is derived from Federal agencies, patient advocacy organizations, industry, and a non-profit membership society.

Neuroscience Forum Funding: 2009

<table>
<thead>
<tr>
<th>Source</th>
<th>Industry</th>
<th>Federal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonprofit</td>
<td>5%</td>
<td>34%</td>
</tr>
</tbody>
</table>

For more information about the forum or to become a member, please contact Bruce Altevogt at (202) 334-3984.
### About the Neuroscience Forum

The 2006 IOM in 2006 established the Forum on Neuroscience and Nervous System Disorders. The forum is designed to provide its members with a venue for exchanging information, sharing individual views, and allowing a structured opportunity for dialogue and discussion while scrutinizing, critical and possibly contentious scientific and policy issues. Representatives from government, industry, academia, patient advocacy organizations, and other interested parties serve as Forum members. It convenes twice a year to create a subject area of mutual interest and concern. At its meetings, the Forum identifies and discusses emerging scientific and policy issues related to basic neuroscience and nervous system disorders, as well as effective clinical interventions and policy options. The Forum also sponsors workshops temporally as an additional mechanism for informing the membership of the Forum, other relevant stakeholders, and the public. Information about past or upcoming meetings is available at the Forum’s website, www.iom.edu/neuroforum.

### About the Institute of Medicine

The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. The mission of the Institute of Medicine improves the health of people everywhere.

### IOM Staff

Bruce Altevogt, Ph.D.  
Project Director  
Sarah Hansen  
Associate Program Officer  
Lisa Taylor  
Senior Project Assistant

### IOM Board on Health Sciences Policy

Andrew M. Page, Ph.D.  
Director

### THE NATIONAL ACADEMIES

Alliances to the Nation on Science, Engineering, and Medicine

For additional information on the Forum on Neuroscience and Nervous System Disorders visit the Forum’s website at www.iom.edu/neuroforum, or call Bruce Altevogt at (202) 334-3984.

### FORUM MEMBERSHIP

**(As of December 2009)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alan Leshner (Chair)</td>
<td>American Association for the Advancement of Science</td>
</tr>
<tr>
<td>Huda Abi</td>
<td>University of Michigan, Ann Arbor</td>
</tr>
<tr>
<td>Marc Bittler</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>Mark Bern</td>
<td>Massachusetts Institute of Technology</td>
</tr>
<tr>
<td>Daniel Burch</td>
<td>Cold Spring Harbor Laboratory</td>
</tr>
<tr>
<td>Denis Choi</td>
<td>Scripps Research Institute</td>
</tr>
<tr>
<td>Timothy Currier</td>
<td>Foundation for the National Multiple Sclerosis Society</td>
</tr>
<tr>
<td>David Cohen</td>
<td>Columbia University, Society for Neuroscience representative</td>
</tr>
<tr>
<td>Richard Frank</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>John Griffl</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Richard Hodes</td>
<td>National Institute on Aging</td>
</tr>
<tr>
<td>Katie Hoed</td>
<td>Michael J. Fox Foundation for Parkinson’s Research</td>
</tr>
<tr>
<td>Steven Hyman</td>
<td>Harvard University</td>
</tr>
<tr>
<td>Thomas Insel</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Mark Mayini</td>
<td>Johnson &amp; Johnson Pharmaceuticals</td>
</tr>
<tr>
<td>Mark Mayini</td>
<td>Johnson &amp; Johnson Pharmaceuticals</td>
</tr>
<tr>
<td>Mark Mayini</td>
<td>Johnson &amp; Johnson Pharmaceuticals</td>
</tr>
<tr>
<td>Huda Akil</td>
<td>University of Michigan, Ann Arbor</td>
</tr>
<tr>
<td>Daniel Burch</td>
<td>Massachusetts Institute of Technology</td>
</tr>
<tr>
<td>Denis Choi</td>
<td>Scripps Research Institute</td>
</tr>
<tr>
<td>Richard Frank</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>John Griffl</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Richard Hodes</td>
<td>National Institute on Aging</td>
</tr>
<tr>
<td>Katie Hoed</td>
<td>Michael J. Fox Foundation for Parkinson’s Research</td>
</tr>
<tr>
<td>Steven Hyman</td>
<td>Harvard University</td>
</tr>
<tr>
<td>Thomas Insel</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Mark Mayini</td>
<td>Johnson &amp; Johnson Pharmaceuticals</td>
</tr>
<tr>
<td>Huda Akil</td>
<td>University of Michigan, Ann Arbor</td>
</tr>
<tr>
<td>Daniel Burch</td>
<td>Massachusetts Institute of Technology</td>
</tr>
<tr>
<td>Denis Choi</td>
<td>Scripps Research Institute</td>
</tr>
<tr>
<td>Richard Frank</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>John Griffl</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Richard Hodes</td>
<td>National Institute on Aging</td>
</tr>
</tbody>
</table>

### FORUM SPONSORSHIP

Financial support for the Forum is derived from federal agencies, patient advocacy organizations, industry, and a non-profit membership society.

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institute of Mental Health</td>
<td>43%</td>
</tr>
<tr>
<td>National Institutes of Health Neuroscience</td>
<td>38%</td>
</tr>
<tr>
<td>National Institute on Drug Abuse</td>
<td>19%</td>
</tr>
<tr>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
<td>9%</td>
</tr>
</tbody>
</table>

### Neuroscience Forum Funding: 2009

<table>
<thead>
<tr>
<th>Source</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonprofit</td>
<td>38%</td>
</tr>
<tr>
<td>Industry</td>
<td>38%</td>
</tr>
<tr>
<td>Federal</td>
<td>24%</td>
</tr>
</tbody>
</table>